A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Clinical trial NCT05406401 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05406401
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-14
- Primary completion
- 2029-04-26
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.